NCCN makes no warranties of any kind whatsoever regarding their
content, use or application and disclaims any responsibility for their application
or use in any way.
Abbreviations: HCT, hematopoietic cell transplantation; HSCs, hematopoietic
stem cells; MM, multiple myeloma; NCCN, National Comprehensive Cancer
Network® (NCCN®); NHL, non-Hodgkin's lymphoma; PBSCs,
peripheral blood stem cells.
References:
- Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and
dexamethasone with transplantation for myeloma. N Engl J Med.
2017;376(14):1311-1320.
- Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow
transplantation as compared with salvage chemotherapy in relapses of
chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med.
1995;333(23):1540-1545.
- Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive
non-Hodgkin’s lymphoma: results of a randomized trial evaluating graft
source and minimal residual disease. J Clin Oncol.
2002;20(9):2344-2352.
- Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization
strategies: future directions. Bone Marrow Transplant.
2009;43(3):181-195.
- Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell
mobilization strategies to improve patient outcomes: consensus guidelines
and recommendations. Biol Blood Marrow Transplant.
2014;20(3):295-308.
- Costa LJ, Miller AN, Alexander ET, et al. Growth factor and patient-adapted
use of plerixafor is superior to CY and growth factor for autologous
hematopoietic stem cells mobilization. Bone Marrow Transplant.
2011;46(4):523-528.
- DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized
double-blind placebo-controlled trial of plerixafor plus granulocyte
colony-stimulating factor compared with placebo plus granulocyte
colony-stimulating factor for autologous stem-cell mobilization and
transplantation for patients with non-Hodgkin’s lymphoma. J Clin
Oncol. 2009;27(28):4767-4773.
- DiPersio JF, Stadtmauer EA, Nademanee A, et al; for the 3102 Investigators.
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem
cells for autologous stem cell transplantation in patients with multiple
myeloma. Blood. 2009;113(23):5720-5726.
- Lemoli RM. New strategies for stem cell mobilization. Mediterr J Hematol
Infect Dis. 2012;4(1):e2012.066. doi:10.4084/MJHID.2012.066.
- Referenced with permission from the NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines®) for Multiple Myeloma V.5.2022. ©
National Comprehensive Cancer Network, Inc. 2022. All rights reserved.
Accessed August 2, 2022. To view the most recent and complete version of the
guideline, go online to www.NCCN.org.
- Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on
stem cell mobilization and engraftment post-peripheral blood stem cell
transplantation in patients with newly diagnosed myeloma. Leukemia.
2007;21(9):2035-2042.
- Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem
cell mobilization after prior lenalidomide in patients with multiple
myeloma. Biol Blood Marrow Transplant. 2009;15(6):718-723.
- Costa LJ, Alexander ET, Hogan KR, et al. Development and validation of a
decision-making algorithm to guide the use of plerixafor for autologous
hematopoietic stem cell mobilization. Bone Marrow Transplant.
2011;46(1):64-69.
- Shaughnessy P, Chao N, Shapiro J, et al. Pharmacoeconomics of hematopoietic
stem cell mobilization: an overview of current evidence and gaps in the
literature. Biol Blood Marrow Transplant. 2013;19(9):1301-1309.
- Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and
remobilization strategies on achieving sufficient stem cell yields for
autologous transplantation. Biol Blood Marrow Transplant.
2008;14(9):1045-1056.